The European Medicines Agency (EMA)

The European Medicines Agency (EMA) is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union. For more information, please visit

EMA RSS Channel

Title Filter      Display #  
# Article Title
1 EMA and US FDA release first conclusions of parallel assessment of quality-by-design applications
2 European Medicines Agency website on suspected side effect reports now in all 23 EU official languages
3 European Medicines Agency boosts EU transparency
4 European Medicines Agency and United States Food and Drug Administration to share manufacturing site inspections
5 European Medicines Agency starts new review of cardiovascular risks of non-selective NSAIDs
6 European Medicines Agency reviews further data on narcolepsy and possible association with Pandemrix
7 European Medicines Agency completes its review of Avastin used in breast cancer
8 European Medicines Agency and ENCePP launch electronic Register of Studies
9 European Medicines Agency and U.S. Food and Drug Administration extend confidentiality arrangements
10 European Medicines Agency holds international workshop on clinical trials
11 European Medicines Agency starts review of Pandemrix
12 EMA and US FDA seek potential candidate companies for joint GMP inspection programme
13 European Medicines Agency starts review of rosiglitazone-containing medicines
14 European Medicines Agency implements internal reorganisation
15 The bacterial challenge - time to react
16 European Medicines Agency review of pandemic vaccines underway
17 European public health agencies evaluate antibiotic resistance of Staphylococcus aureus
18 European Medicines Agency recommendations on extension of shelf life for Tamiflu
19 EMEA-coordinated PROTECT project has been accepted for funding
20 EMEA, EC and Health Canada agree implementation plan for confidentiality arrangement
21 EMEA recommends suspension of the marketing authorisation of Raptiva (efalizumab)
22 European Medicines Agency welcomes continuation of D:A:D study
23 EMEA recommends the suspension of the marketing authorisation of Ionsys (fentanyl hydrochloride)
24 EMEA recommends suspension of the marketing authorisation of Acomplia
25 European Medicines Agency recommends update of product information of Tysabri
26 European Medicines Agency recommends restricting the use of oral moxifloxacin-containing medicines
27 EMEA recommendation on use of angiotensin II receptor antagonists during pregnancy
28 Wyeth Europa Ltd withdraws its marketing authorisation application for Pristiqs (desvenlafaxine)
29 Actelion withdraws its application for an extension of indication for Zavesca
30 Risk of peripheral neuropathy with Sebivo (telbivudine)
31 EMEA recommends new warnings and contraindications for rosiglitazone
32 EMEA recommends withdrawal of marketing authorisations for cough medicines containing clobutinol
World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]